Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Financial Results

Astrana Health Net Income Surges 3,372% in Q3 2026 as Revenue Tops $1 Billion

Astrana Health reported a significant turnaround in profitability for the third quarter of 2026, with net income rising to $12.95 million from a low base in the prior year. Revenue grew to $1,024 million, supported by the maturation of risk-bearing provider cohorts and expansion in key markets.

Surgery, hospital, doctor, care. Stock photo illustrating Astrana Health's financial results story.
Astrana Health, Inc. · Photo: sasint / Pixabay
Results at a glance · $ Million
Metric Q3-26Q3-25
Revenue 1,024956.05
Pretax Income 32.225.67
Net Income 12.950.37
Diluted EPS 0.260.01
Net Income YoY
+3,372.4%

Key highlights

  • Revenue reached $1,024 million, a 7.1% increase compared to $956.05 million in Q3 2025
  • Net income soared 3,372.4% year-over-year to $12.95 million
  • Pretax income improved to $32.22 million from $5.67 million in the prior-year period
  • Diluted EPS rose to $0.26, up from $0.01 in the third quarter of 2025
  • Net receivables increased to $530.9 million as of September 30, 2026

How the Period Went

Astrana Health achieved a notable scale milestone in the third quarter of 2026, with revenue climbing to $1,024 million from $956.05 million a year earlier. This top-line expansion was accompanied by a dramatic shift in the bottom line, as net income rose 3,372.4% to $12.95 million, compared to $0.37 million in the same period last year. This surge in profitability primarily reflects the stabilization of medical cost trends and the increased contribution from full-risk capitation contracts. Diluted EPS followed this trajectory, reaching $0.26 for the quarter, while pretax income nearly sextupled to $32.22 million, highlighting improved operating leverage across the company's physician networks.

Margins and Profitability

Profitability during the quarter was bolstered by the maturation of the company's Care Partners segment, which benefited from favorable risk-adjustment sweeps and improved clinical outcomes. While net income reached $12.95 million, the company's balance sheet reflected a decrease in cash to $396.2 million from year-end 2025 levels. Simultaneously, net receivables rose significantly to $530.9 million, suggesting higher billing activity from capitated arrangements. The company's P/E ratio of 47.0 reflects market expectations of continued earnings growth following this period of margin expansion. Management noted that medical cost performance improved organically, particularly in expansion markets like Texas, helping to offset persistent Medicaid membership attrition.

Business Overview

  • Operates a physician-centric, technology-powered healthcare platform focused on value-based care delivery
  • The Care Partners segment manages a network of aligned providers under capitated risk arrangements
  • The Care Delivery segment provides direct primary and specialty care through physical clinical sites
  • The Care Enablement segment offers the technology and administrative infrastructure for population health management
  • Serves approximately 1.5 million patients across Medicare, Medicaid, and commercial health plans

Financial Context and Industry Landscape

The quarterly performance occurs amidst a challenging broader healthcare environment characterized by rising medical utilization and high pharmacy costs, particularly for GLP-1 medications. Astrana's 9.36% quarterly share price gain outpaced some peers as the market reacted to its ability to manage medical loss ratios effectively. With a market capitalization of $2.18 billion and an RSI of 58.9, the stock remains in a neutral technical position. The company's shift toward full-risk arrangements, which are expected to account for 82% of capitation revenue by year-end, aligns with industry-wide efforts to move toward outcome-based reimbursement models in the face of rising 2027 medical cost projections.

Astrana Health, Inc. share price · last month
Line chart of Astrana Health, Inc.'s share price over the last month, from $36.90 on 19 Oct → $32.87 on 16 Nov; our story on 6 Nov at $39.01.

Down 15.7% since our story on 6 Nov: $39.01 when we broke it → $32.87 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$36.90
20 Oct$38.58
21 Oct$37.35
22 Oct$38.01
23 Oct$37.45
26 Oct$37.23
27 Oct$36.94
28 Oct$36.67
29 Oct$36.62
30 Oct$36.53
2 Nov$36.88
3 Nov$36.73
4 Nov$39.67
5 Nov$39.01
6 Nov$34.50
9 Nov$33.77
10 Nov$32.18
11 Nov$32.94
12 Nov$31.77
13 Nov$31.80
16 Nov$32.87
Recent quarters and guidance
DateAnnouncementAmount
05 Nov 2026Q3 2026 total revenueSource: prnewswire.com$1.02 Billion
05 Nov 2026FY 2026 revenue guidance (narrowed)Source: stocktitan.net–
06 Aug 2026Q2 2026 total revenueSource: ir.astranahealth.com$972.5 Million
06 Aug 2026FY 2026 revenue guidanceSource: stocktitan.net–
07 May 2026Q1 2026 total revenueSource: prnewswire.com$965.1 Million
02 Mar 2026FY 2025 total revenueSource: prnewswire.com$3.18 Billion

Management commentary

“Our third quarter results demonstrate the growing impact of Astrana's physician-centric, AI-native healthcare operating platform and our team's continued focus on execution.”

Brandon Sim, President and Chief Executive Officer
Astrana Health, Inc. · financial snapshot
Share price$39.01
Market cap$2.2B
Revenue (annual)$3.2B
P/E (TTM)47.0×
1-month price change+5.43%
SectorHealthcareMedical Care Facilities

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Astrana Health, Inc. announcing its financial results for the quarter ended September 30, 2026.

Read the filing ↗

Track Astrana Health, Inc. live

Get the next Astrana Health, Inc. SEC filing seconds after it lands.

More in Results & Earnings

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.